MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Edison Oncology Holding Corp. (‘Edison Oncology’), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (‘Apollomics’), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors. EO1001 is a potent irreversible tyrosine kinase inhibitor (TKI) that has demonstrated inhibition of EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) as a single agent in laboratory studies. “We are thrilled
The post Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial appeared first on Pharma Mirror Magazine.
